Nektar says rezpegaldesleukin shows early biomarker response in Phase 2b REZOLVE-AD atopic dermatitis study

Bitget2026/09/30 14:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Nektar Therapeutics disclosed new biomarker results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin in moderate-to-severe atopic dermatitis.
Findings were presented in a late-breaking oral session at the EADV Congress 2026.
Data showed early biological activity consistent with the drug’s regulatory T-cell mechanism, with changes emerging within the first weeks of dosing.
Early molecular shifts tracked with later clinical improvement in treated patients, supporting rezpegaldesleukin’s positioning as a broader immune-modulating approach.
Results underpin the company’s plan to advance the program into Phase 3 development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609301030PR_NEWS_USPR_____SF59259) on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Nektar says rezpegaldesleukin shows early biomarker response in Phase 2b REZOLVE-AD atopic dermatitis study

You may also like

Crypto prices